Literature DB >> 28684637

Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Katherine R Walter1,2,3, Merit L Goodman1,2,3, Hari Singhal4, Jade A Hall1,2,3, Tianbao Li5, Sean M Holloran1,2,3, Gloria M Trinca1,2,3, Katelin A Gibson1,2,3, Victor X Jin5, Geoffrey L Greene6, Christy R Hagan7,2,3.   

Abstract

The progesterone receptor (PR) regulates transcriptional programs that drive proliferation, survival, and stem cell phenotypes. Although the role of native progesterone in the development of breast cancer remains controversial, PR clearly alters the transcriptome in breast tumors. This study identifies a class of genes, Interferon (IFN)-stimulated genes (ISGs), potently downregulated by ligand-activated PR which have not been previously shown to be regulated by PR. Progestin-dependent transcriptional repression of ISGs was observed in breast cancer cell line models and human breast tumors. Ligand-independent regulation of ISGs was also observed, as basal transcript levels were markedly higher in cells with PR knockdown. PR repressed ISG transcription in response to IFN treatment, the canonical mechanism through which these genes are activated. Liganded PR is robustly recruited to enhancer regions of ISGs, and ISG transcriptional repression is dependent upon PR's ability to bind DNA. In response to PR activation, key regulatory transcription factors that are required for IFN-activated ISG transcription, STAT2 and IRF9, exhibit impaired recruitment to ISG promoter regions, correlating with PR/ligand-dependent ISG transcriptional repression. IFN activation is a critical early step in nascent tumor recognition and destruction through immunosurveillance. As the large majority of breast tumors are PR positive at the time of diagnosis, PR-dependent downregulation of IFN signaling may be a mechanism through which early PR-positive breast tumors evade the immune system and develop into clinically relevant tumors.Implications: This study highlights a novel transcriptional mechanism through which PR drives breast cancer development and potentially evades the immune system. Mol Cancer Res; 15(10); 1331-40. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28684637      PMCID: PMC5626608          DOI: 10.1158/1541-7786.MCR-17-0180

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

Review 1.  Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.

Authors:  Andy J Minn; E John Wherry
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

Review 2.  Role of phosphorylation in progesterone receptor signaling and specificity.

Authors:  Christy R Hagan; Andrea R Daniel; Gwen E Dressing; Carol A Lange
Journal:  Mol Cell Endocrinol       Date:  2011-09-16       Impact factor: 4.102

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

5.  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.

Authors:  L Tung; M K Mohamed; J P Hoeffler; G S Takimoto; K B Horwitz
Journal:  Mol Endocrinol       Date:  1993-10

6.  Architecture of the human regulatory network derived from ENCODE data.

Authors:  Mark B Gerstein; Anshul Kundaje; Manoj Hariharan; Stephen G Landt; Koon-Kiu Yan; Chao Cheng; Xinmeng Jasmine Mu; Ekta Khurana; Joel Rozowsky; Roger Alexander; Renqiang Min; Pedro Alves; Alexej Abyzov; Nick Addleman; Nitin Bhardwaj; Alan P Boyle; Philip Cayting; Alexandra Charos; David Z Chen; Yong Cheng; Declan Clarke; Catharine Eastman; Ghia Euskirchen; Seth Frietze; Yao Fu; Jason Gertz; Fabian Grubert; Arif Harmanci; Preti Jain; Maya Kasowski; Phil Lacroute; Jing Jane Leng; Jin Lian; Hannah Monahan; Henriette O'Geen; Zhengqing Ouyang; E Christopher Partridge; Dorrelyn Patacsil; Florencia Pauli; Debasish Raha; Lucia Ramirez; Timothy E Reddy; Brian Reed; Minyi Shi; Teri Slifer; Jing Wang; Linfeng Wu; Xinqiong Yang; Kevin Y Yip; Gili Zilberman-Schapira; Serafim Batzoglou; Arend Sidow; Peggy J Farnham; Richard M Myers; Sherman M Weissman; Michael Snyder
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

7.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

Review 8.  Molecular determinants of context-dependent progesterone receptor action in breast cancer.

Authors:  Christy R Hagan; Carol A Lange
Journal:  BMC Med       Date:  2014-02-20       Impact factor: 8.775

9.  Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Authors:  A R Daniel; A L Gaviglio; T P Knutson; J H Ostrander; A B D'Assoro; P Ravindranathan; Y Peng; G V Raj; D Yee; C A Lange
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

10.  Progesterone receptor modulates ERα action in breast cancer.

Authors:  Hisham Mohammed; I Alasdair Russell; Rory Stark; Oscar M Rueda; Theresa E Hickey; Gerard A Tarulli; Aurelien A Serandour; Aurelien A A Serandour; Stephen N Birrell; Alejandra Bruna; Amel Saadi; Suraj Menon; James Hadfield; Michelle Pugh; Ganesh V Raj; Gordon D Brown; Clive D'Santos; Jessica L L Robinson; Grace Silva; Rosalind Launchbury; Charles M Perou; John Stingl; Carlos Caldas; Wayne D Tilley; Jason S Carroll
Journal:  Nature       Date:  2015-07-08       Impact factor: 49.962

View more
  17 in total

1.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

2.  Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.

Authors:  Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-16

3.  O-GlcNAc-Dependent Regulation of Progesterone Receptor Function in Breast Cancer.

Authors:  Gloria M Trinca; Merit L Goodman; Evangelia K Papachristou; Clive S D'Santos; Prabhakar Chalise; Rashna Madan; Chad Slawson; Christy R Hagan
Journal:  Horm Cancer       Date:  2017-09-19       Impact factor: 3.869

4.  KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity.

Authors:  Romi Gupta; Parmanand Malvi; Keshab Raj Parajuli; Radoslav Janostiak; Suresh Bugide; Guoping Cai; Lihua Julie Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

5.  MX 2 is a novel regulator of cell cycle in melanoma cells.

Authors:  Marina Juraleviciute; Joanna Pozniak; Jérémie Nsengimana; Mark Harland; Juliette Randerson-Moor; Patrik Wernhoff; Assia Bassarova; Geir Frode Øy; Gunhild Trøen; Vivi Ann Flørenes; David Timothy Bishop; Meenhard Herlyn; Julia Newton-Bishop; Ana Slipicevic
Journal:  Pigment Cell Melanoma Res       Date:  2019-11-13       Impact factor: 4.693

6.  The eIF2α Kinase GCN2 Modulates Period and Rhythmicity of the Circadian Clock by Translational Control of Atf4.

Authors:  Salil Saurav Pathak; Dong Liu; Tianbao Li; Nuria de Zavalia; Lei Zhu; Jin Li; Ramanujam Karthikeyan; Tommy Alain; Andrew C Liu; Kai-Florian Storch; Randal J Kaufman; Victor X Jin; Shimon Amir; Nahum Sonenberg; Ruifeng Cao
Journal:  Neuron       Date:  2019-09-12       Impact factor: 17.173

7.  Progesterone promotes immunomodulation and tumor development in the murine mammary gland.

Authors:  Lauryn R Werner; Katelin A Gibson; Merit L Goodman; Dominika E Helm; Katherine R Walter; Sean M Holloran; Gloria M Trinca; Richard C Hastings; Howard H Yang; Ying Hu; Junping Wei; Gangjun Lei; Xiao-Yi Yang; Rashna Madan; Alfredo A Molinolo; Mary A Markiewicz; Prabhakar Chalise; Margaret L Axelrod; Justin M Balko; Kent W Hunter; Zachary C Hartman; Carol A Lange; Christy R Hagan
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

8.  Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.

Authors:  Sean M Holloran; Bakhtiyor Nosirov; Katherine R Walter; Gloria M Trinca; Zhao Lai; Victor X Jin; Christy R Hagan
Journal:  Mol Cell Endocrinol       Date:  2020-05-11       Impact factor: 4.102

9.  Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing.

Authors:  Tianbao Li; Qi Liu; Nick Garza; Steven Kornblau; Victor X Jin
Journal:  Genome Med       Date:  2018-04-17       Impact factor: 11.117

10.  The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.

Authors:  Rilin Deng; Chaohui Zuo; Yongqi Li; Binbin Xue; Zhen Xun; Yanxia Guo; Xiaohong Wang; Yan Xu; Renyun Tian; Shengwen Chen; Qian Liu; Jinwen Chen; Jingjing Wang; Xiang Huang; Huiyi Li; Mengmeng Guo; Xintao Wang; Miaomiao Yang; Zhihui Wu; Jinfeng Wang; Jiahuan Ma; Jun Hu; Guangdi Li; Songqing Tang; Zhengkun Tu; Hongbin Ji; Haizhen Zhu
Journal:  Cell Mol Immunol       Date:  2020-09-22       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.